Research Article
No access
Published Online: 26 September 2006

The Role of Antimicrobial Use in the Epidemiology of Resistant Pneumococci: A 10-Year Follow Up

Publication: Microbial Drug Resistance
Volume 12, Issue Number 3

Abstract

The relative effects of risk factors on the prevalence of resistant pneumococcal clones are hard to determine. Our aim was to evaluate the effect of risk factors on the prevalence of resistant pneumococci in Iceland in 2003 and compare these data with results of identical studies performed in 1993 and 1998. A randomized sample of 1,107 children was chosen from all 2,532 children 1 to 6 years old living in four communities. Pneumococci were carried by 64% of the 824 children enrolled and 9.5% were penicillin nonsusceptible (PNSP), as opposed to 8.1% (1998) and 8.5% (1993), and multiresistant strains of serotype 6B were 2.5% compared to 7.5% and 7.7% (p < 0.001). Antimicrobial use had declined in 10 years from 1.5 to 1.0 courses/child per year. The only significant risk factor for carriage of PNSP and erythromycin-resistant pneumococci was antimicrobial consumption. The multiresistant type 6B strains disappeared from the areas with the lowest antimicrobial use but maintained unchanged prevalence in the area with the highest use. The number of erythromycin- resistant, penicillin-susceptible strains of all pneumococci (37/475, 7.8%) increased significantly from the previous studies (7/353, 2.0%, 1998, and 2/390, 0.5%, 1993). This observation is associated with increased use of macrolides, especially azithromycin, in one of the study areas. Spread of novel resistant clones appears to be the main reason for rapid and significant changes in pneumococcal resistance rates. The choice of antimicrobial class appears to influence the selective environment favoring particular resistant clones.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

cover image Microbial Drug Resistance
Microbial Drug Resistance
Volume 12Issue Number 3Fall 2006
Pages: 169 - 176
PubMed: 17002543

History

Published online: 26 September 2006
Published in print: Fall 2006

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Vilhjalmur A. Arason
Department of Family Medicine, University of Iceland, Solvangur, Hafnarfjordur, Iceland.
Johann A. Sigurdsson
Department of Family Medicine, University of Iceland, Solvangur, Hafnarfjordur, Iceland.
Helga Erlendsdottir
Department of Clinical Microbiology, Landspitali University Hospital, Reykjavik, Iceland.
Sigurdur Gudmundsson
Directorate of Public Health, Reykjavik, Iceland.
Dr. Karl G. Kristinsson
Department of Clinical Microbiology, Landspitali University Hospital, Reykjavik, Iceland.
Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top